Wall Street's Insights Into Key Metrics Ahead of Alkermes (ALKS) Q4 EarningsZacks Investment Research • 02/24/26
Will Alkermes (ALKS) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research • 02/17/26
Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine MarketBusiness Wire • 02/12/26
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026Business Wire • 02/11/26
Alkermes plc (ALKS) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/13/26
FDA Grants Breakthrough Therapy Designation to ALKS' Narcolepsy DrugZacks Investment Research • 01/07/26
Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1Business Wire • 01/06/26
Avadel Pharmaceuticals Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avadel Pharmaceuticals plc - AVDLPRNewsWire • 12/12/25
Alkermes plc (ALKS) Presents at Evercore 8th Annual Healthcare Conference TranscriptSeeking Alpha • 12/06/25
ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's ProposalZacks Investment Research • 11/20/25
Alkermes Ups Its Avadel Bid To $2.37 Billion In A Buyout Battle With LundbeckInvestors Business Daily • 11/19/25